Increasing HPV vaccination coverage in Switzerland: a return-on-investment analysis
Attaining the 90% VCR targets by 2030 is projected to generate favorable economic returns for the Swiss government. Specifically, over the lifetime of the vaccinated cohorts, a CHF1 investment is estimated to yield societal and fiscal returns of CHF1.5 and 1.2, respectively.
Authors
- Vincent Daniels (ORCID: https://orcid.org/0000-0002-3226-7231)
- Mark P. Connolly (ORCID: https://orcid.org/0000-0002-1886-745X)
- Ugne Sabale (ORCID: https://orcid.org/0000-0003-1874-8730)
- Nikolaos Kotsopoulos (ORCID: https://orcid.org/0000-0002-8248-7697)
- Andrea Favre-Bulle
- Andrew Pavelyev
- Siti Aisyah Nur
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Demos (US)
- University of Groningen (NL)
- National and Kapodistrian University of Athens (GR)
- MSD (Switzerland) (CH)
- MSD K.K. (Japan) (JP)
- MSD (Lithuania) (LT)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Public Health Solutions (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1080/13696998.2025.2532458
- Citations
- 1
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Merck
- Meso Scale Diagnostics